Feng Xu

Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3.

Feng Xu, T. Schall, Qingge Xu, 2007, Bioorganic & medicinal chemistry letters.

Suppressing the intestinal farnesoid X receptor/sphingomyelin phosphodiesterase 3 axis decreases atherosclerosis.

Shuyang Zhang, M. Bustin, F. Gonzalez, 2021, The Journal of clinical investigation.

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

F. Raal, D. Blom, E. Stein, 2015, The Lancet.

Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia

F. Raal, E. Stein, N. Honarpour, 2013, Circulation.

Abstract 17016: Trial Assessing Long-Term Use of PCSK9 Inhibition in Patients with Genetic LDL Disorders (TAUSSIG): Efficacy and Safety in Patients with Homozygous Familial Hypercholesterolemia Receiving Lipid Apheresis

F. Raal, E. Stein, E. Bruckert, 2014 .

Trial evaluating evolocumab, a pcsk9 antibody, in patients with homozygous fh (tesla): Results of the randomized, double-blind, placebo-controlled trial

F. Raal, D. Blom, E. Stein, 2014 .

Optimization of 2-aminothiazole derivatives as CCR4 antagonists.

T. Schall, Qingge Xu, G. Tonn, 2006, Bioorganic & medicinal chemistry letters.

Efficacy of evolocumab (AMG 145) in patients with PCSK9 gain-of-function mutations

G. Watts, M. Harada‐Shiba, H. Makino, 2014 .